TARA (43) CRDL (52) CHRS (36) ABOS (38) ⌘ Pro Terminal →

Sutro Biopharma Inc. (STRO) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell STRO stock right now?

Sutro Biopharma Inc. (STRO) currently earns a Roarable Rating of D- (Sell — SELL) with 36/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is STRO's 12-month price target and RQD AI Jury consensus?

STRO's 12-month base price target is $8.2 (range $6.4 to $46.04), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$9.10 -0.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.08

Sutro Biopharma Inc. (STRO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $151.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on STRO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is STRO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Sutro Biopharma Inc. (NASDAQ: STRO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $9.10 (-0.44% 1D, market cap $151.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, STRO ranks #641 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does STRO compare to TARA and CRDL in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), STRO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TARA (Protara Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -34.7%, cap $148.9M) and CRDL (Cardiol Therapeutics Inc. (Class A)) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $141.2M). Among the 5-stock peer group, STRO leads on earnings multiple (N/A) while TARA leads on capital efficiency (-34.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for STRO?

▼

Per STRO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001382101), Sutro Biopharma Inc. generated $102.5M in revenue (+65.2% YoY), -$191.0M in net income, and -$177.2M in free cash flow against $173.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.08 (-0.27%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for STRO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY STRO SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (22% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 25.2 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$14.27-23.3% Next Q

Q2 (-2Q)

Grade D$10.94-14.7% Next Q

Q3 (-1Q)

Grade E$9.33-2.5% Next Q

Current

Grade D-$9.10-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a STRO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While STRO currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($15.39) and Max Pain ($9.56) forces dealer call-delta covering toward $46.04.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $STRO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “STRO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

25.230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE5% OF RANGE

L: $7$9.10H: $44

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on STRO

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (32)

11/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like STRO

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring STRO)

✓Walkthrough of STRO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

STRO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -75.15%⚡ TESTING RESISTANCE

2026-10-30O $9.04H $9.40L $8.80C $9.10VOL 122.3K

RES: $11.19SUP: $7.32SMA50: $15.39SMA200: $23.03

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

STRO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 STRO Butterfly Map → + Track STRO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +65.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on STRO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for STRO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for STRO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (STRO)

Health Care Rank #641 of 1016 ⚔️ TARA vs STRO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (STRO vs. TARA, CRDL, CHRS, ABOS)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sutro Biopharma Inc. (STRO) ranks #641 by composite RQD confidence (36/100, grade D-) and #609 by equity capitalization ($151.6M). Within this direct 5-issuer industry benchmark cohort, STRO leads on earnings valuation at N/A trailing P/E, while TARA leads on capital efficiency and profitability with -34.7% ROIC and — gross margin. CRDL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with STRO at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
STRO ACTIVE Sutro Biopharma Inc.	D-	36/100	—	—	-35.0%	-0.44%	$151.6M	Benchmark Subject
TARA Protara Therapeutics Inc.	D-	43/100	—	—	-34.7%	-1.59%	$148.9M	/tara-vs-stro →
CRDL Cardiol Therapeutics Inc. (Class A)	D+	52/100	—	—	—	-5.13%	$141.2M	/crdl-vs-stro →
CHRS Coherus Oncology Inc.	D-	36/100	—	—	-35.0%	-7.60%	$138.8M	/chrs-vs-stro →
ABOS Acumen Pharmaceuticals Inc.	D-	38/100	—	—	-35.0%	-90.82%	$165.6M	/abos-vs-stro →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001382101

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sutro Biopharma Inc. (STRO) reported GAAP revenue of $102.5M (+65.2% vs. FY2024 revenue of $62.0M , and -33.3% cumulative change since FY2023) , GAAP net income of -$191.0M, operating cash flow of -$177.2M, and free cash flow of -$177.2M (+7.5% YoY). On the balance sheet, STRO closed FY2025 with $173.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$102.5M	-$191.0M	-$177.2M	-$177.2M	$173.8M	—
FY2024 (FY)	2024-12-31	$62.0M	-$227.0M	-$191.5M	-$191.5M	$387.2M	—
FY2023 (FY)	2023-12-31	$153.7M	-$107.0M	-$111.6M	-$111.6M	—	—

3. STRO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is STRO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does STRO compare to TARA and CRDL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for STRO?

Where is STRO trading relative to its 50-day, 200-day, and 52-week technical levels?

STRO last traded at $9.10 (-0.44% on volume of 122,356 shares), positioning the stock -40.87% below its 50-day simple moving average ($15.39) and -60.49% below its 200-day simple moving average ($23.03). Across its 52-week range of $7.15 to $43.85, STRO sits at the 5.3% percentile with a 14-day RSI of 25.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($7.96 to $10.24).

STRO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell STRO stock right now?

Sutro Biopharma Inc. (STRO) currently earns a Roarable Rating of D- (Sell — SELL) with 36/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is STRO's 12-month price target and RQD AI Jury consensus?

STRO's 12-month base price target is $8.2 (range $6.4 to $46.04), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: STRO RQD Cockpit STRO 12M Forecast STRO Earnings & Move STRO Dividends & DRIP STRO Insiders & 13F STRO Whale Options STRO Profit Sankey STRO News & Why

ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

STRO — Sutro Biopharma Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:42:32Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, STRO scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Pillar breakdown: Fundamental Cash Engine 6/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow 6/20 (institutional accumulation and options positioning); Insider Conviction 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 8/20 (Beta 1.0; sector sensitivity); Forensic Balance Sheet 11/20 (Altman Z 2.5; Piotroski F 4/9; Debt/Equity 0.5).

Investor implications: the two weakest pillars (Cash Engine and Insider Conviction) indicate that the current equity case rests less on present cash generation and more on future pipeline outcomes, which the supplied data does not quantify. The Forensic Balance Sheet pillar is the strongest of the five but still sits in the lower half of its range, implying the company is not in a comfortable liquidity position relative to its burn. Upside drivers would need to come from pipeline progress or a change in flow dynamics; valuation tradeoffs are severe given negative margins and a 0% FCF yield, and the low market capitalization of $151.6M means the equity is highly sensitive to financing events that the source data does not describe.

Business

Sutro Biopharma Inc. is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Biological Products (No Diagnostic Substances). Per the company profile, its market capitalization is $0.2B. Not available in source data: product list, customer base, and revenue model detail.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$102.5M	$-158.4M	$-191.0M	N/A	$-177.2M	$58.1M	N/A
FY 2024	$62.0M	$-238.5M	$-227.0M	N/A	$-191.5M	$190.3M	N/A
FY 2023	$153.7M	$-89.3M	$-107.0M	N/A	$-111.6M	N/A	N/A

Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC of -35%. Per the RQD pillars, the Altman Z-Score is 2.5, the Piotroski F-Score is 4/9, and Debt/Equity is 0.5. Cash declined from $190.3M (FY 2024) to $58.1M (FY 2025) while free cash flow remained negative in every reported period, indicating ongoing cash consumption. Debt is not available in source data for any period.

Recent Catalysts & News Wire Analysis

Per the news feed, H.C. Wainwright reiterated a buy rating on STRO.
Per the news feed, a first patient was dosed in a Phase 1 trial of STRO-006, an ITGB6-targeting ADC in advanced solid tumors.
Per the news feed, the company announced participation at the 17th Annual World ADC Conference.
Per the news feed, a second antibody-linked cancer drug entered human testing in under a year.
Per the news feed, shares pulled back 6.85% to $14.27 testing a support zone; two items carry this headline, sourced from third-party sites.
Risk watch: the 52-week range of $7.15 - $43.85 and the current price of 9.1 indicate substantial price deterioration; all news items are tagged YELLOW.
Proprietary signals: none recorded in the Butterfly graph.

Open Questions

What is the current debt balance and maturity schedule, given that debt is N/A across all reported periods?
What funding runway exists against FY 2025 free cash flow of $-177.2M and year-end cash of $58.1M?
What is the EPS trajectory, since EPS is N/A in every period?
Who are the institutional holders and what are their recent 13F position changes?
What are the clinical milestones and timelines for the STRO-006 program?

STRO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sutro Biopharma Inc. (STRO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to STRO Debate Forum (3) ↓

🟡 MARKET WIRE Investing.com • 7h ago

H.C. Wainwright reiterates Sutro Biopharma stock rating at buy

Investing.com report covering Sutro Biopharma Inc. (STRO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 10h ago

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors

Yahoo Finance report covering Sutro Biopharma Inc. (STRO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 13h ago

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

Yahoo Finance UK report covering Sutro Biopharma Inc. (STRO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 16h ago

Sutro's second antibody-linked cancer drug entered human testing in less than a year.

Stock Titan report covering Sutro Biopharma Inc. (STRO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 19h ago

Sutro Biopharma (STRO) Pulls Back 6.85% to $14.27 as Shares Test Key Support Zone - Volume Nodes

https://www.siam.in/ report covering Sutro Biopharma Inc. (STRO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Sutro Biopharma (STRO) Climbs to $11.26 as Buyers Test Upper Resistance - High Low Breadth

https://www.siam.in/ report covering Sutro Biopharma Inc. (STRO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH www.dars.gov.et • 1d ago

STRO Q2 2026 Earnings: Wider-Than-Expected Loss Pressures Shares - Strong Earnings Momentum

www.dars.gov.et report covering Sutro Biopharma Inc. (STRO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo • 11h ago

Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates

Axsome (AXSM) delivered earnings and revenue surprises of +63.77% and +5.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

STRO Bull vs. Bear Conversation Board — What's Your Call at $9.10?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON STRO 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $8.01 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is STRO (D- • RQD 36/100) a Buy at $9.10?

Welcome to the STRO (Sutro Biopharma Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.01 (-23.0%)

Spot @ $9.10

Pump the brakes on STRO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on STRO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Sutro Biopharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $10.56 (+16.0%)

Spot @ $9.10

STRO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on STRO, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $9.10 (52-wk range $7.15 - $43.85), any beat on forward guidance forces shorts and underweight funds to chase.